| Autor: |
Sasmith R. Menakuru, Adelina Priscu, Vijaypal Dhillon, Ahmed Salih |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Hematology Reports, Vol 14, Iss 3, Pp 235-239 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2038-8330 |
| DOI: |
10.3390/hematolrep14030032 |
| Popis: |
Patients with sickle cell anemia often receive multiple red blood cell (RBC) transfusions during their lifetime. Hyperhemolysis is a life-threatening phenomenon of accelerated hemolysis and worsening anemia that occurs when both transfused RBCs and autologous RBCs are destroyed. The level of hemoglobin post-transfusion is lower than pre-transfusion levels, and patients are usually hemodynamically unstable. Hyperhemolysis must be differentiated from a delayed hemolytic transfusion reaction during which destruction of transfused RBC is the cause of anemia. Hyperhemolysis syndrome can be differentiated into acute (within seven days) and chronic forms (after seven days) post-transfusion. The authors present a case of acute hyperhemolysis syndrome in a patient with sickle cell anemia refractory to steroids and IVIG, which are the treatment of choice. The patient was treated with tocilizumab, combined with supportive measures of erythropoietin, iron, vitamin B12, and folate. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
